ANALYSIS: Experimental Treatment Preserves the Bladder in 89% of Patients

Introduction: Avoiding Removal—Real Hope

For many patients with bladder cancer, the news that standard treatment has failed often means there is only one possible outcome: radical cystectomy, a major surgical procedure involving the complete removal of the bladder. A Phase 3 study published in The Lancet Oncology, reported on July 27, 2026, by GlobeNewswire on behalf of CG Oncology, offers an alternative whose results deserve serious attention: an experimental treatment that preserved the bladder in 89% of patients at one year.

The treatment in question, called cretostimogene grenadenorepvec, was tested as a monotherapy—that is, used alone, without any other concomitant treatment—in patients whose bladder cancer no longer responded to the standard treatment, BCG (Bacillus Calmette-Guérin). Understanding what these results actually show—as well as their significant methodological limitations—allows us to gauge the exact scope of this breakthrough without falling into either excessive enthusiasm or unwarranted skepticism.

The clinical problem this treatment aims to address

When standard BCG treatment is no longer sufficient

BCG has long been the standard of care for certain forms of non-invasive bladder cancer—that is, cancer that has not yet invaded the organ’s muscular wall. This treatment, administered directly into the bladder, stimulates the local immune system to fight cancer cells. However, in some patients, this standard treatment ceases to be effective, or the cancer recurs despite treatment—a clinical situation known as BCG resistance.

This resistance to standard treatment is not a rare occurrence: it affects a significant proportion of patients treated over time, and it presents medical teams with a difficult choice among limited options. It is precisely this therapeutic gap that experimental treatments like the one studied here aim to fill, in the hope of offering a genuine alternative to radical surgery.

For these patients, historical options were limited and often radical. Radical cystectomy—the complete removal of the bladder—remains an effective option from an oncological standpoint, but it profoundly transforms the patient’s life: it requires the creation of a new pathway for urine drainage, with major implications for quality of life, body image, and daily independence. Finding an alternative capable of controlling the cancer without resorting to this surgery therefore represents a major clinical challenge for these patients.

The principle behind the experimental treatment being tested

Cretostimogene grenadenorepvec belongs to a category of treatments called oncolytic virotherapies—viruses modified in the laboratory to specifically target cancer cells, replicate within them, and then destroy them, while potentially stimulating an additional immune response against the tumor. This approach differs from conventional chemotherapy in its targeted mechanism of action, designed to spare surrounding healthy tissue to a greater extent.

In this study, the treatment was administered as monotherapy, meaning that patients did not receive any other concomitant anticancer treatment during the trial. This methodological choice allows for a clear isolation of the effect of the experimental treatment itself, without the potential influence of combination therapy, which could have obscured the interpretation of the results.

What strikes me about this approach is the shift in logic: instead of destroying cancer cells solely through chemotherapy or radiation, a modified virus is used as a precision tool. This is a concrete illustration of how modern biotechnology is reinventing tools once thought to belong exclusively to nature.

Key Results from the Clinical Trial

A high complete response rate

The trial, conducted as a single-arm study, included 112 patients. The observed complete response rate was 75.5%—meaning that more than three-quarters of the treated patients showed no detectable signs of cancer after treatment, according to the study’s evaluation criteria. This is a notable result for a patient population whose cancer had already been resistant to standard treatment, a clinical context generally associated with a poorer prognosis.

This complete response rate forms the basis for the most widely discussed finding of this study: bladder preservation. Among patients who responded to treatment, the bladder could be preserved in the vast majority of cases, thereby avoiding the removal surgery that would otherwise have been considered.

Bladder Preservation and Duration of Response Over Time

The key figure from this study is the rate of bladder preservation: 89% at twelve months, and still 81% at twenty-four months. In other words, more than eight out of ten patients who respond to this treatment retain their bladder two years later—a result that spares these patients major surgery with lasting consequences for their quality of life.

The median duration of response observed is at least 27.9 months, suggesting that the treatment’s effect, in responding patients, is not limited to a temporary benefit lasting just a few months but extends over a prolonged period. In terms of safety, no treatment-related grade 3 or higher side effects were reported in this study—an encouraging sign, given that grade 3 and higher generally denote severe side effects requiring significant medical intervention.

The figure that stands out most to me is not the initial response rate, but its durability over more than two years. A treatment that works for a few months and then wears off would not carry the same clinical weight as a treatment whose effect persists over such a long period, especially for patients who have already experienced failure with first-line therapy.

Methodological limitations that should not be overlooked

A trial without a direct comparison group

Despite these encouraging results, a significant methodological limitation must be highlighted with the same rigor as the positive findings. This was a single-arm trial, meaning there was no direct comparison group in this specific study—no placebo arm, nor an arm receiving an alternative standard of care, against which to compare the results obtained.

This type of design limits scientific certainty regarding the exact extent of the benefit of this treatment compared to other therapeutic options that are currently available or under development. Without a direct comparison, it becomes more difficult to precisely isolate the portion of the benefit attributable specifically to the experimental treatment, as opposed to other factors such as the natural course of the disease in some patients or effects related to the close medical monitoring provided as part of a clinical trial.

A modest sample size for a Phase 3 trial

The other limitation concerns the sample size. With 112 patients, this trial remains modest by Phase 3 standards, which typically involve hundreds or even thousands of participants in order to detect rarer effects or confirm the statistical robustness of the observed results. A smaller sample size increases the margin of uncertainty surrounding the reported figures, particularly regarding the exact response rates and bladder preservation rates.

These limitations do not call into question the validity of the results observed in this specific patient population, but they call for sound caution before generalizing these figures to all patients with BCG-resistant bladder cancer, or before considering this treatment definitively superior to existing options without a rigorous direct comparison.

I believe we must resist the temptation to turn a single-arm trial into a definitive verdict, even when the numbers are impressive. Scientific rigor requires us to acknowledge a promising result while honestly recognizing what it cannot yet prove with absolute certainty.

What This Means for Patients and Clinical Practice

An Additional Option in the Therapeutic Arsenal

For patients whose bladder cancer is resistant to BCG, this experimental treatment represents an additional option to consider, alongside other approaches currently in development or already available. The possibility of preserving the bladder in the vast majority of patients who respond to treatment could—if these results are confirmed in future comparative trials—change part of the care pathway for this patient population.

It is important to note, however, that this treatment does not necessarily replace BCG as a first-line therapy—it is specifically intended for patients in whom this standard treatment has already failed. Its exact role in the bladder cancer treatment sequence will need to be clarified by further research and by the relevant regulatory authorities, who will evaluate the entire dossier before making any decision regarding expanded approval.

Toward Comparative Trials to Confirm These Results

The next logical step for this treatment would be to conduct comparative clinical trials, with a direct comparison group, in order to precisely measure the extent of the benefit relative to the options currently available for this patient population. This type of trial would also help better define the treatment’s safety profile across a larger and more diverse sample of patients.

Pending such confirmation, the results published in The Lancet Oncology represent a genuine and well-documented advance that deserves to be communicated accurately: a promising treatment with robust results regarding bladder preservation and a favorable safety profile in this specific trial, though its definitive superiority over other options remains to be demonstrated by larger comparative studies.

For the medical teams who care for these patients on a daily basis, this type of result fuels a broader discussion on how to integrate oncolytic virotherapies into existing protocols, alongside other immunotherapy approaches already used in urologic oncology. This integration will take time and will depend largely on the results of future comparative trials.

What I appreciate about the way these results are presented is the absence of any absolute promises. The discussion focuses on bladder preservation in the vast majority of patients, not on a universal miracle cure—and that is exactly the level of precision this type of research deserves.

Conclusion: Real Progress, Framed by Clear Limitations

This experimental treatment based on cretostimogene grenadenorepvec offers a significant clinical outcome for patients with BCG-resistant bladder cancer: bladder preservation in 89% of patients at one year and 81% at two years, with a complete response rate of 75.5% and no severe side effects reported in this trial of 112 patients.

These figures must nevertheless be interpreted in light of the study’s limitations: a single-arm design with no direct comparison group and a relatively small sample size for a Phase 3 trial. This treatment represents a concrete and encouraging avenue for avoiding surgical removal in certain patients, but its definitive place in the therapeutic arsenal remains to be confirmed by larger comparative trials.

By Maxime Marquette, columnist

ANALYSIS: A Phase 3 Trial That Could Change the Lives of Patients with Bladder Cancer